Intranasal inserts to treat chronic respiratory and CNS diseases
A platform of long-acting intranasal solid-dosage forms for local and Nose-To-Brain drug delivery
Dianosic is clinical-stage biotech designing transformative long-acting resorbable intranasal solid-dosage forms to overcome the delivery challenges of current chronic respiratory and CNS therapies.ch
The administration of long-acting (up to 12 months) intranasal solid dosage forms enables the treatment of multiple respiratory diseases at low doses, delivered directly at or near the site of action in a controlled fashion.
Addresses a major challenge in patient adherence to treatment.
For brain diseases, this approach has the potential to overcome major drug-delivery barriers by exploiting the “nose-to-brain” pathway and bypass the blood-brain barrier.
Excellent nasal retention without compromising patient comfort or quality of life.
Our Science
Dianosic develops a platform of cutting-edge intranasal solid dosage forms. It enables sustained local and Nose-To-Brain drug delivery based on a proprietary know-how in long-acting, low-dose, resorbable polymer inserts.
One platform. Three programs. DIA01-R in Chronic Allergic Rhinitis DIA02-S in Chronic Rhinosinusitis DIA03-N2BS in refractory Schizophrenia
Partner with us
Dianosic de-risks formulation, preclinical in vivo activities and ensures Clinical readiness. We integrate your API into our proprietary intranasal solid dosage form and also provide access to our internal programs.
